Data reported for gefitinib use in Caucasian EGFR mutation-positive non-small-cell lung cancer patients

被引：0
作者：
Lake, Francesca
机构：
来源：
FUTURE ONCOLOGY | 2013年 / 9卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：930 / 930
页数：1
相关论文
共 50 条
[21]   First-line treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) by gefitinib [J].
Moiseyenko, V. ;
Procenko, S. A. ;
Levchenko, E. V. ;
Barchuk, A. S. ;
Matsko, D. E. ;
Moiseyenko, F. V. ;
Ivantsov, A. O. ;
Iyevleva, A. G. ;
Mitiushkina, N. V. ;
Imyanitov, E. N. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[22]   ROLE OF QUIESCENCE CANCER STEM CELLS IN THE GEFITINIB RESISTANCE IN EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER [J].
Hidayat, Moulid ;
Takahashi, Fumiyuki ;
Tajima, Ken ;
Nurwidya, Fariz ;
Wirawan, Aditya ;
Kanemaru, Ryota ;
Koinuma, Yoshika ;
Hayakawa, Daisuke ;
Tajima, Manabu ;
Matsumoto, Naohisa ;
Kanamori, Koichiro ;
Takeda, Ikuko ;
Kato, Motoyasu ;
Kobayashi, Isao ;
Shimada, Naoko ;
Takahashi, Kazuhisa .
RESPIROLOGY, 2017, 22 :18-19
[23]   Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial [J].
Paz-Ares, L. ;
Tan, E. -H. ;
O'Byrne, K. ;
Zhang, L. ;
Hirsh, V. ;
Boyer, M. ;
Yang, J. C. -H. ;
Mok, T. ;
Lee, K. H. ;
Lu, S. ;
Shi, Y. ;
Lee, D. H. ;
Laskin, J. ;
Kim, D. -W. ;
Laurie, S. A. ;
Kolbeck, K. ;
Fan, J. ;
Dodd, N. ;
Marten, A. ;
Park, K. .
ANNALS OF ONCOLOGY, 2017, 28 (02) :270-277
[24]   EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer [J].
Shih, JY ;
Gow, CH ;
Yang, PC .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (02) :207-208
[25]   Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly [J].
Gabriele Minuti ;
Armida D’Incecco ;
Federico Cappuzzo .
Drugs & Aging, 2015, 32 :907-916
[26]   Overall survival of patients with EGFR mutation-positive non-small-cell lung cancer treated with erlotinib, gefitinib or afatinib under drug programmes in Poland - real-world data [J].
Brzozowska, Melania ;
Wierzba, Waldemar ;
Szafraniec-Burylo, Sylwia ;
Czech, Marcin ;
Majkut, Gabriela ;
Polowinczak-Przybylek, Joanna ;
Potemski, Piotr ;
Sliwczynski, Andrzej .
ARCHIVES OF MEDICAL SCIENCE, 2021, 17 (06) :1618-1627
[27]   Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer [J].
Ramalingam, Suresh S. ;
Yang, James C-H ;
Lee, Chee Khoon ;
Kurata, Takayasu ;
Kim, Dong-Wan ;
John, Thomas ;
Nogami, Naoyuki ;
Ohe, Yuichiro ;
Mann, Helen ;
Rukazenkov, Yuri ;
Ghiorghiu, Serban ;
Stetson, Daniel ;
Markovets, Aleksandra ;
Barrett, J. Carl ;
Thress, Kenneth S. ;
Janne, Pasi A. .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (09) :841-+
[28]   OVERCOMING ERLOTINIB RESISTANCE IN EGFR MUTATION-POSITIVE NON-SMALL-CELL LUNG CANCER CELLS BY TARGETING SURVIVIN [J].
Okamoto, K. ;
Okamoto, I. ;
Hatashita, E. ;
Kuwata, K. ;
Yamaguchi, H. ;
Kita, A. ;
Yamanaka, K. ;
Ono, M. ;
Nakagawa, K. .
ANNALS OF ONCOLOGY, 2012, 23 :85-85
[29]   Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Clash of the Generations [J].
Shah, Riyaz ;
Lester, Jason F. .
CLINICAL LUNG CANCER, 2020, 21 (03) :E216-E228
[30]   Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer [J].
Corral, Jesus ;
Mok, Tony S. ;
Nakagawa, Kazuhiko ;
Rosell, Rafael ;
Lee, Ki Hyeong ;
Migliorino, Maria Rita ;
Pluzanski, Adam ;
Linke, Rolf ;
Devgan, Geeta ;
Tan, Weiwei ;
Quinn, Susan ;
Wang, Tao ;
Wu, Yi-Long .
FUTURE ONCOLOGY, 2019, 15 (24) :2795-2805
12345